Industry 5.0 in action: AI-driven continuous manufacturing for RNA therapeutics

RNA therapies hold immense potential for treating a wide range of diseases, but their manufacturing requires innovative solutions. 
In a recent presentation at TIDES USA: Oligonucleotide and Peptide Therapeutics, Aaron Cowley, Chief Scientific Officer at ReciBioPharm, explored how ReciBioPharm's CP1 platform is revolutionising RNA production, leveraging continuous manufacturing, inline process analytical technology (PAT), and artificial intelligence (AI).

What is the CP1 platform?

ReciBioPharm's CP1 is a revolutionary continuous manufacturing platform that integrates all steps of RNA production, from in vitro transcription (IVT) to fill and finish. By eliminating the stop-and-start nature of batch production, CP1 enhances efficiency, reduces costs and accelerates development timelines.

How does CP1 leverage PAT?

CP1 utilises inline PAT to provide real-time insights into critical quality attributes throughout production. Tools like RAMAN spectroscopy, multi-angle light scattering and others monitor RNA concentration, integrity, purity and LNP characteristics. This data-driven approach allows for immediate identification and resolution of potential issues, ensuring consistent product quality.

As we head towards Industry 5.0, how are machine learning and AI used in CP1?

In line with Industry 5.0 principles, CP1 employs machine learning and a digital twin simulator to optimise processes. By analysing real-time data and historical production runs, predictive models for yield and purity are generated. This iterative feedback loop enhances the efficiency, robustness, and adaptability of the manufacturing process, ultimately ensuring high-quality RNA therapies for patients.

To learn more about how CP1 could support your next RNA project, watch our Chief Scientific Officer, Aaron Cowley’s presentation at TIDES USA: Oligonucleotide and Peptide Therapeutics.

Fill in the form below and access the video: